Building an Inclusive Future: EDI Initiatives at Moores Cancer Center
|
Exciting new initiatives are underway to build an inclusive future at Moores, inspired by valuable stakeholder feedback. The Moores Office of Equity, Diversity, and Inclusion is launching four new affinity groups (Women’s Network, LGBTQ+ Network, Disability Empowerment Network, and Veterans Network), the Moores Leadership Academy to prepare future leaders, and the Inclusive Excellence Seminar Series to promote the power of diversity in research. Learn More>>
|
|
|
Skaggs Therapeutics: Discovery, Development, Practice, and Policy (DDPP) Seminar Series
|
Each week, DDPP features global experts who present on a range of medicinal research (e.g., AI-driven drug discovery and microbiome-based therapeutics) to spark innovation and collaboration to improve human health. Learn More>>
|
Bridging Theory and Technologies in Physical Oncology
|
The Gordon Research Conferences, Physical Science of Cancer is an international scientific conference to advance science through presenting innovative and unpublished research, prioritizing time for discussion, and fostering informal interactions among scientists of all career stages. The conference features diverse speakers and discussion leaders, poster sessions, and opportunities for informal networking through afternoon free time and communal meals. Learn More & Apply>>
|
|
|
FEATURED FUNDING OPPORTUNITIES
|
Letter of Intent (LOI) Deadline: March 4, 2025
Application Deadline: April 4, 2025
Budget: $300,000/year for 3 years
|
LOI Deadline: March 4, 2025
Application Deadline: April 4, 2025
Budget: $150,000 per year over 3 years
|
Application Deadline: May 19, 2025
Budget: $475,000/year for 4 years
|
LOI Deadline: September 17, 2025
Application Deadline: October 17, 2025
Budget: $499,999/year for 5 years
|
Application Deadline: February 5, 2025
Budget: $499,999/year for 5 years
|
|
|
|
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: A randomized Phase I trial
|
Jyoti Mayadev, MD (Solid Tumor Therapeutics)
|
|
|
| Bile acid synthesis impedes tumor-specific T cell responses during liver cancer
|
Jin Lee, PhD (Solid Tumor Therapeutics [STT]), Debanjan Dhar, PhD (STT), and Gen-Sheng Feng, PhD (Cancer Biology and Signaling)
|
|
|
|
A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis
|
Rohit Loomba, MD (Cancer Control)
|
|
|
|
